FDA Extends Review Timeline for Eli Lilly's Oral Obesity Drug Orforglipron

The U.S. Food and Drug Administration (FDA) extended the review period for Eli Lilly's oral GLP-1 weight-loss candidate, orforglipron.

The new expected decision date is April 10. This delays the original plan, which anticipated approval by the end of February.

The delay gives rival Novo Nordisk more time to capture market share. Novo Nordisk launched its own oral weight-loss drug in December.

Following the delay news, Eli Lilly's stock declined 4% on one trading day.